Evidence map›Paper›PMID 18385251›Full record

ArticleJournal of virology2008

Comprehensive immunological evaluation reveals surprisingly few differences between elite controller and progressor Mamu-B*17-positive simian immunodeficiency virus-infected rhesus macaques.

Nicholas J Maness, Levi J Yant, Chungwon Chung, John T Loffredo, Thomas C Friedrich, Shari M Piaskowski, Jessica Furlott, Gemma E May, Taeko Soma, Enrique J León and 6 more

Abstract readComparative Study
In one paragraph

Article in Journal of virology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 57 citations in OpenAlex.

  1. HLA-B*14:02-Restricted Env-Specific CD8Journal of virology · 2017
    Trial
  2. Trial
  3. Antiretroviral therapy blocks natural selection on protective and disease-susceptible HLA-B alleles in HIV-1 infection.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Acute-Phase CD4Journal of virology · 2018
    Article
  9. Review
  10. Journal of virology · 2018
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Nicholas J ManessWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin 53711, USA.
Levi J Yant
Chungwon Chung
John T Loffredo
Thomas C Friedrich
Shari M Piaskowski
Jessica Furlott
Gemma E May
Taeko Soma
Enrique J León
Nancy A Wilson
Helen Piontkivska
Austin L Hughes
John Sidney
Alessandro Sette
David I Watkins
La Jolla Institute for Immunology · USUniversity of Wisconsin–Madison · USKent State University · USUniversity of South Carolina · US

Funding

ZOLEDRONATE PREVENTS BONE LOSS IN OVARIECTOMIZED RHESUS MONKEYSP51RR000167 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI WATKINS, DAVID I · 1985 to 2011
$106.7M
The Functional Significance of Cytotoxic T Lymphocyte EscapeR01AI052056 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI WATKINS, DAVID I · 2003 to 2024
$8.3M
MHC-bound, SIV-derived, CTL &HTL EpitopesR24RR015371 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI WATKINS, DAVID I · 2000 to 2011
$8.1M
A NOVEL, LOGICAL APPROACH TO HIV VACCINE DEVELOPMENTR01AI049120 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI WATKINS, DAVID I · 2001 to 2009
$7.6M
EXTRAMURAL RES FACIL CONST: REPRODUCTIVE, GROWTH &DVMT, MENOPAUSEC06RR020141 · NCRR · UNIVERSITY OF WISCONSIN MADISON · PI CADWALLADER, MARTIN · 2004 to 2004
$3.6M
EXTRAMURAL REGIONAL FACILITIES CONSTRUCTIONC06RR015459 · NCRR · UNIVERSITY OF WISCONSIN MADISON · PI CADWALLADER, MARTIN · 2000 to 2000
$1.9M
POLYMORPHISM &EVOLUTION OF MHC GENESR01GM043940 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI HUGHES, AUSTIN L. · 1990 to 2010
$1.5M
Correlates of elite control of SIVR21AI068586 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI FRIEDRICH, THOMAS C. · 2006 to 2007
$506k
NCRR NIH HHS C06 RR015459NCRR NIH HHS C06 RR020141NCRR NIH HHS P51 RR000167NCRR NIH HHS R24 RR015371NCRR NIH HHS RR020141-01NCRR NIH HHS RR15459-01NIAID NIH HHS R01 AI049120NIAID NIH HHS R01 AI052056NIAID NIH HHS R21 AI068586NIGMS NIH HHS R01 GM043940NIGMS NIH HHS R01 GM43940
6 · The paper itself

Abstract

The association between particular major histocompatibility complex class I (MHC-I) alleles and control of human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) replication implies that certain CD8(+) T-lymphocyte (CD8-TL) responses are better able than others to control viral replication in vivo. However, possession of favorable alleles does not guarantee improved prognosis or viral control. In rhesus macaques, the MHC-I allele Mamu-B*17 is correlated with reduced viremia and is overrepresented in macaques that control SIVmac239, termed elite controllers (ECs). However, there is so far no mechanistic explanation for this phenomenon. Here we show that the chronic-phase Mamu-B*17-restricted repertoire is focused primarily against just five epitopes-VifHW8, EnvFW9, NefIW9, NefMW9, and env(ARF)cRW9-in both ECs and progressors. Interestingly, Mamu-B*17-restricted CD8-TL do not target epitopes in Gag. CD8-TL escape variation occurred in all targeted Mamu-B*17-restricted epitopes. However, recognition of escape variant peptides was commonly observed in both ECs and progressors. Wild-type sequences in the VifHW8 epitope tended to be conserved in ECs, but there was no evidence that this enhances viral control. In fact, no consistent differences were detected between ECs and progressors in any measured parameter. Our data suggest that the narrowly focused Mamu-B*17-restricted repertoire suppresses virus replication and drives viral evolution. It is, however, insufficient in the majority of individuals that express the "protective" Mamu-B*17 molecule. Most importantly, our data indicate that the important differences between Mamu-B*17-positive ECs and progressors are not readily discernible using standard assays to measure immune responses.

Indexed as

Amino Acid SequenceAnimalsCD8-Positive T-LymphocytesEpitopesHistocompatibility Antigens Class IMacaca mulattaReading FramesSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusViral ProteinsVirus ReplicationEpitopesHistocompatibility Antigens Class IViral Proteins

Identifiers

PMID18385251
PMCPMC2395202
OpenAlexW2136015446

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.